Dr. Dowlati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106Phone+1 216-844-3951Fax+1 216-844-5759- Is this information wrong?
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1998 - 2000
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 1999
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
- Universite de L'Etat a Liege Faculty of MedicineClass of 1992
Certifications & Licensure
- OH State Medical License 1999 - 2025
- IA State Medical License 1998 - 2005
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
- Top MD Consumers Checkbook
Clinical Trials
- SU5416 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 May 01
- Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer Start of enrollment: 1999 Apr 01
- Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2000 May 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.Cinta Hierro, Jordi Rodon, Andreas Wicki, Martin D Forster, Sarah P Blagden, Jun Yin, Joel M Reid, Helene Muller, Natasa Cmiljanovic, Vladimir Cmiljanovic, Filip Janku...> ;Cancers. 2024 Mar 13
- A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
- Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.David S Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G Christensen, Josée Morin, Diane Potvin, Demiana Fal...> ;Lung Cancer. 2024 Apr 1
- Join now to see all
Press Mentions
- Case Comprehensive Cancer Center Awarded $8.9 Million to Expand Access to Clinical TrialsMay 16th, 2019
- National Comprehensive Cancer Network Awards Grants for Small Cell Lung Cancer ResearchSeptember 4th, 2023
Hospital Affiliations
- University Hospitals Cleveland Medical CenterCleveland, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: